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Summary
Hepatitis C virus (HCV) entry is dependent on host
cell molecules tetraspanin CD81, scavenger recep-
tor BI and tight junction proteins claudin-1 and
occludin. We previously reported a role for CD81/
claudin-1 receptor complexes in HCV entry;
however, the molecular mechanism(s) driving
association between the receptors is unknown. We
explored the molecular interface between CD81
and claudin-1 using a combination of bioinformatic
sequence-based modelling, site-directed mutagen-
esis and Fluorescent Resonance Energy Transfer
(FRET) imaging methodologies. Structural model-
ling predicts the first extracellular loop of claudin-1
to have a flexible beta conformation and identifies
a motif between amino acids 62–66 that interacts
with CD81 residues T149, E152 and T153. FRET
studies confirm a role for these CD81 residues
in claudin-1 association and HCV infection.
Importantly, mutation of these CD81 residues has
minimal impact on protein conformation or HCV
glycoprotein binding, highlighting a new functional
domain of CD81 that is essential for virus entry.
Introduction
Many viruses initiate infection through a multistep process
involving multiple host cell receptor proteins (for review,
see Grove and Marsh, 2011). Although the molecular
interaction of viruses with individual receptor proteins has
been elucidated in great detail, the more dynamic process
of multi-protein engagement has proven a greater chal-
lenge. The sequential engagement of receptors provides
a co-ordinated process to regulate virus internalization
and offers new targets for anti-viral intervention.
Hepatitis C virus (HCV) interacts with tetraspanin CD81
and scavenger receptor BI (SR-BI) (Pileri et al., 1998;
Scarselli et al., 2002) and permissive cells express tight
junction proteins claudin-1 and occludin, epidermal
growth factor receptor and Niemann-Pick C1-like 1 protein
(Burlone and Budkowska, 2009; Ploss et al., 2009;
Dorner et al., 2011; Lupberger et al., 2011; Meredith et al.,
2012; Sainz et al., 2012), highlighting the multi-step
nature of the internalization process. At the present time,
the role these individual entry factors play and how they
co-ordinate HCV entry is unknown (Evans et al., 2007;
Cukierman et al., 2009; Krieger et al., 2010).
CD81 was the first cellular protein identified to bind
HCV and is a member of the tetraspanin family of proteins
that are widely expressed and involved in multiple bio-
logical functions, including cell proliferation and cell–cell
adhesion (Hemler, 2005). The diverse role of tetraspanins
in the infectivity of various pathogens, including the
malarial plasmodium parasite, HIV-1, Influenza and
human papilloma virus, and in cancer prompted a search
for ligands, antibodies or small molecules that selectively
inhibit tetraspanin function (Spoden et al., 2008; Hassuna
et al., 2009; Wang et al., 2011). Although several antibod-
ies targeting the CD81 second extracellular loop (ECL2)
have been reported to inhibit HCV infection in vitro and in
vivo (Meuleman et al., 2008; Farquhar et al., 2012), they
have also been shown to promote immune cell prolifera-
tion and to activate multiple cellular processes, limiting
their therapeutic potential (Levy and Shoham, 2005;
Coffey et al., 2009).
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cellular microbiology
In contrast, there is limited evidence for tight junction
protein association with HCV, suggesting an indirect
role for claudin-1 and occludin in virus internalization
(Meredith et al., 2012). We (Harris et al., 2008; 2010) and
others (Kovalenko et al., 2007; Cukierman et al., 2009)
have shown a direct interaction of claudins with tet-
raspanins, supporting a model where CD81–claudin-1
receptor complexes define HCV internalization. The
claudin superfamily of four transmembrane proteins play
an essential role in the formation and maintenance of tight
junctions in epithelial and endothelial cells. However,
claudin-1 has been reported to associate with CD81 at the
basolateral surface of polarized hepatoma cells, suggest-
ing a role for non-junctional pools of claudin-1 in HCV
entry (Harris et al., 2010). Mutagenesis of the first
claudin-1 extracellular loop (ECL1) ablated both its asso-
ciation with CD81 and HCV entry (Evans et al., 2007;
Cukierman et al., 2009; Harris et al., 2010), illustrating the
essential role of the receptor complex in HCV infection.
Furthermore, antibodies specific for claudin-1 ECL1
inhibit HCV infection by reducing claudin-1 association
with CD81 (Fofana et al., 2010; Krieger et al., 2010), high-
lighting the therapeutic value of targeting the receptor
complex to limit infection.
We investigated the molecular interface between CD81
and claudin-1 using a combination of bioinformatic
sequence-based modelling, site-directed mutagenesis
and Fluorescent Resonance Energy Transfer (FRET).
Although the crystal structure of human CD81 ECL2 is
known (PDB 1G8Q) (Kitadokoro et al., 2001; Drummer
et al., 2002; 2005), no X-ray or NMR structural data exists
for any member of the claudin family. We generated a
homology model for claudin-1 ECL1 that predicts amino
acid regions 33–35 and 62–66 to associate with CD81
ECL2 residues T149, E152 and T153. We used this model
to guide the genesis and in vitro screening of a panel of
claudin-1 and CD81 mutants. We demonstrate an essen-
tial role for CD81 residues T149, E152 and T153 to asso-
ciate with claudin-1. Importantly, these mutations had no
impact on protein conformation or HCV E2 binding and
ablate HCV entry, highlighting the novel function of these
CD81 residues. These observations increase our under-
standing of CD81/claudin-1 association and provide a
platform for the computational design of peptides and
small molecules to disrupt receptor complexes and inhibit
viral infection.
Results
Modelling claudin-1 ECL1 and its interaction with CD81
We previously reported that recombinant claudin-1 ECL1
bound dimeric CD81 ECL2 (Harris et al., 2010), demon-
strating an association between the extracellular loops of
these two proteins. A BLAST search of claudin-1 against all
sequences with determined structures in the PDB data-
base revealed limited homology; however, a 30% identity
was found between claudin-1 residues 4–57 and residues
21–74 of Cj0915, a hexameric hotdog fold thioesterase of
Campylobacter jejuni (PDB:3D6L), suggesting that ECL1
adopts a flexible beta conformation. Lacking a full-length
homologue, we widened our search to include theoretical
structures. This search identified the only published model
of a tetraspanin, CD81 (PDB: 2AVZ; Seigneuret, 2006)
as the most suitable whole length homologue, with a
sequence similarity of 45% along the 211 amino acid length
of the protein. We used this CD81 template, including the
crystal structure co-ordinates of ECL2 (Kitadokoro et al.,
2001), to predict a structure for claudin-1 ECL1 tethered at
either end to transmembrane regions appropriately packed
within a four transmembrane region bundle (Fig. 1A).
Our model predicts claudin-1 ECL1 to consist mostly of
beta turns with few structural constraints and identifies two
regions that interface with CD81 ECL2 (Fig. 1A). The first
region (amino acids 33–35) orientates the loops to form a
stable complex, whereas the second (amino acids 63–66)
interacts directly with K148, T149, E152 and T153 of CD81
(Fig. 1A). The surface area of the CD81/claudin-1 ECL
interface was calculated to be 1005 Å2, representing 7% of
the accessible surface area of each protein.
To evaluate our CD81/claudin-1 model we studied the
effect of HCV receptor inactivating claudin-1 mutations
I32M and E48K (Evans et al., 2007), previously reported
to ablate claudin-1 association with CD81 (Harris et al.,
2010). Molecular models of I32M (Fig. 1B) and E48K
(Fig. 1C) mutants predicted substantial changes in the
structure and orientation of ECL1, with the introduction of
a short a helix and increased distances between CD81
interacting residues. Most markedly, for the claudin-1
I32M mutant, the Q63 – CD81 E152 distance increased to
over 10 Å, leading to a dramatic loss of surface area for
protein interaction. Similarly, mutating claudin-1 E48K
induced a loss of three of the four key residue pairings,
suggesting a profound impact on loop orientation and
diminished association with CD81. The double I32M/
E48K mutant induced significant changes in ECL1 orien-
tation and interaction with CD81 contact residues
(Fig. 1D). We previously reported that receptor inactive
claudin-7 does not interact with CD81, however, mutation
of residues M32I and K48E conferred viral receptor activ-
ity and CD81 association (Harris et al., 2010). In silico
modelling of claudin-7 predicted no association with CD81
(Fig. 1E). However, the double mutant adopted a struc-
ture closer to that of claudin-1 in which claudin-7 C64 was
positioned to interact with CD81 E152 (Fig. 1F).
To further study our CD81/claudin-1 model we studied a
panel of claudin-1 mutants, previously reported to disrupt
HCV receptor activity (Cukierman et al., 2009), for their
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effect(s) on claudin-1 ECL1 structure and association with
CD81 (Harris et al., 2010). In silico screening classified
the claudin-1 mutants into three groups: group I mutants
W30A, I32A, I32M, D38A, E48K, G49A and W51A,
showed a withdrawal or disruption of interfacing regions
and no association with CD81; group II mutants T42A,
M52A, S53A and N72A, showed minimal structural altera-
tion(s) and a continued association with CD81; and group
III mutants L50A, C54A and C64A, showed an altered
structure and association with different CD81 residues
L162, I182, N184 and F186 (Table 1). To assess claudin-1
mutant association with CD81, we expressed N-terminal
Fig. 1. Structural modelling of claudin-CD81 association. Ribbon models of the ECL1 domain of native claudin-1 (A) or I32M (B), E48K (C)
and I32M/E48K (D) mutants with CD81 ECL2 (PDB: 1G8Q). Claudin-1 is depicted according to its predicted secondary structure (alpha
helices in red, beta turn in white) with CD81 in green, key interacting residues are labelled. The interacting regions include claudin-1 residues
33–35 and 63–66, and CD81 residues K148, T149, E152 and T153. I32M and E48K claudin-1 mutations alter key inter-residue distances and
interactions with CD81. Model of the ECL1 domain of native claudin-7 (E) or M32I/K48E mutant (F) with the CD81 ECL. Mutagenesis of
claudin-7 relocates the loop around C64 to a position similar to that of claudin-1 and withdraws a prominent loop away from the region of
claudin-CD81 interaction. Images were produced using the Chimera program (University of San Francisco).
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AcGFP–claudin fusion proteins to quantify expression
and interaction with DsRED-CD81. All tagged claudin-1
mutants localized at the plasma membrane (Fig. 2A) and
exhibited similar levels of surface expression (Fig. 2B).
FRET studies confirmed our in silico predictions of the
effect(s) of claudin-1 mutations on CD81 association.
Group I mutants showed no significant FRET with CD81,
whereas group II and III mutants showed similar FRET
values to wild-type (WT) claudin-1 (Fig. 2C). All of the
mutants were co-transfected as fusion constructs in a
two-hybrid screen with a WT CD81 ‘trap’, these assays
showed that all of the claudin-1 molecules in groups II and
III associated with CD81 whereas members of group I
failed to interact (Fig. 2D). The mutants supported varying
levels of HCVpp infection (Fig. 2E). Importantly, all group
I mutants lacked viral receptor activity whereas group II
mutants supported HCVpp entry at comparable levels to
WT claudin-1 (Fig. 2E). In contrast, HCVpp failed to infect
293-T cells expressing group III claudin-1 mutants, dem-
onstrating that the altered claudin-1-CD81 interaction
does not support HCV entry (Table 1). In summary, these
results validate our model and demonstrate the value of a
structural modelling approach to predict the functional
impact of claudin-1 mutations on HCVpp infection.
Identifying CD81 residues that interact with claudin-1
Our model predicts that CD81 residues K148, T149, E152
and T153 interact with claudin-1 residues 63–66 (Fig. 1).
To validate the model we substituted the selected CD81
residues to alanine and studied mutant protein association
with claudin-1 and viral receptor activity. WT and mutant
proteins were tagged at their N-terminus with DsRED and
expressed in the CD81-negative HepG2 hepatoma cell
line. All mutants localized to the plasma membrane, with
minimal evidence of intracellular staining (Fig. 3A). Fur-
thermore, we confirmed that none of the changes altered
the ability of CD81 to dimerize with WT AcGFP–CD81 by
FRET (Fig. 3B). We recently isolated a number of mAbs
that recognize conformation-dependent epitopes in CD81
ECL2 that neutralize HCV infection (Farquhar et al., 2012).
Among these mAbs we identified clones 2s155 and 1s337
that preferentially recognize dimeric CD81 ECL2 (Fig. 3C).
In contrast, mAb 2s20 bound monomeric and dimeric
CD81 with similar values (Fig. 3C). All three mAbs bound
cell surface expressed CD81 (Fig. 3D), consistent with a
dimeric CD81 structure (Seigneuret, 2006). We used these
mAbs as tools to probe CD81 conformation by flow cytom-
etry. Since all proteins were DsRED tagged anti-CD81
mAb binding was expressed relative to fluorophore expres-
sion (Fig. 3D). mAbs 2s155 and 1s337 bound HepG2 cells
expressing WT and mutant CD81 proteins with compara-
ble fluorescent intensities, demonstrating a native confor-
mation for the mutants (Fig. 3E). Several CD81 mutants
bound mAb 1s337 with greater fluorescent intensities com-
pared with WT (Fig. 3E), suggesting a modest change in
protein conformation.
Mutation of T149, E152 and T153 residues to alanine
reduced CD81 FRET with claudin-1, whereas replace-
ment of residue K148 had no significant effect (Fig. 4A).
Table 1. Predicted effect(s) of claudin-1 mutations on CD81:claudin-1 association.
HCV
receptor
activity
ECL1
orientationa
Disruption of
Q63-V66 and
withdrawal
from E152
Orientation of
interacting
residues
disrupted
Predicted to
interact with
CD81
Mutant
grouping
Claudin-1 mutation
WT + WT No No Yes –
W30A - Projecting Yes Yes No I
I32A - Projecting Yes Yes No I
I32M - Withdrawn Yes Yes No I
D38A - Withdrawn Yes Yes No I
E48K - Withdrawn Yes Yes No I
I32M/E48K - Withdrawn Yes Yes No I
G49A - Projecting Yes Yes No I
W51A - Projecting Yes Yes No I
T42A + WT No No Yes II
M52A + WT Yes Yes Yes II
S53A + WT No Yes Yes II
N72A + WT No No Yes II
L50A - WT No No Yes III
C54A - Projecting Yes Yes Yes III
C64A - Projecting Yes Yes Yes III
Claudin-7 mutation
WT - Withdrawn Yes Yes No I
M32I/K48E + WT No No Yes –
a. WT – wild-type position; Withdrawn – moved away from CD81; Projecting – displaced into region occupied by CD81 in WT.
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These data confirm that the main loop interactions involve
T149, E152 and T153, but that K148, although within
reasonable range for interaction may play a role in the
steric fitting of the two loops rather than in specific inter-
actions with claudin-1 residues. To ascertain whether the
mutations perturb CD81 interaction with HCV glycoprotein
E2, CHO cells were transduced to express DsRED
tagged mutants and evaluated for their ability to bind HCV
strains H77 and JFH-1 E2 glycoprotein by flow cytometry.
HCV E2 glycoproteins bound to CHO cells expressing WT
and mutant CD81 (Fig. 4C), suggesting a minimal pertur-
bation of the HCV E2 binding site. HEK 293-T cells natu-
rally lack claudin-1 expression and transduction to
express claudin-1 renders them sensitive to HCVpp entry
(Evans et al., 2007). Comparable levels of HCV E2 bound
to 293-T and 293-T-claudin-1 by flow cytometry (Mean FI
of 62 and 79 respectively), suggesting that claudin-1
expression does not modulate CD81-E2 association. It is
worth noting that CD81 mutants E152A and T153A bound
higher levels of both E2 glycoproteins. HepG2 cells
expressing T149A, E152A or T153A CD81 mutants
showed minimal evidence for HCVpp infection, whereas
Fig. 2. Effect of claudin-1 mutations on protein localization, CD81 association and HCV infection.
A. 293-T cells were transfected to express wild-type (WT) AcGFP–claudin-1 and mutants and their localization assessed by confocal
microscopy.
B. Cell surface expression of AcGFP–claudin mutants was determined using the Zeiss profiling function to trace cell boundaries, the data
shown is the average MFI of 10 cell profiles, the data are representative of three transfection experiments.
C. %FRET between AcGFP–claudin-1 mutants and DsRED-CD81 in transfected 293-T cells. None of the mutants in group I (W30A, I32A,
D38A, G49A and W51A) showed any significant interaction with CD81. The mean %FRET values are derived from triplicate estimates within a
single experiment and are representative of two further experiments. The mean plus 2 SD of non-specific FRET values observed in parental
non-transfected is indicated by the dashed line and represents the threshold for the assay. The diminution in %FRET signal for the members
of group I relative to the other two groups was significant (Kruskal Wallis test, P < 0.01).
D. Two-hybrid screening of interactions between mutant claudin-1 and WT CD81. None of the claudin-1 mutants in group I showed evidence
for association in vitro.
E and F. Infectivity of HCVpp (E) and MLVpp (F) in parental 293-T cells and those transfected to express AcGFP–claudin-1 WT and mutants.
293-T cells expressed comparable levels of WT and claudin-1 mutants. Data are expressed as specific infectivity where the value of an
envelope deficient pseudoparticle is subtracted from both HCVpp and MLVpp relative light unit (RLU) signals. The dashed line represents the
mean plus 2 SD of HCVpp infection of claudin-1-negative parental 293-T cells; levels of infection below this threshold are considered negative.
The data presented are from a single experiment and are representative of two independent experiments.
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Fig. 3. Effect of CD81 mutations on protein localization, antigenicity and HCV E2 binding. HepG2 cells were transduced to express wild-type
(WT) DsRED-CD81 and mutant proteins and their localization assessed by confocal microscopy (A). %FRET between DsRED-CD81 mutants
and AcGFP–CD81 in transfected 293-T cells, The mean values are derived from triplicate estimates which are representative of three further
experiments (B). Anti-CD81 mAbs and rabbit anti-MBP were tested at 5 mg ml-1 for their reactivity with monomeric and dimeric MBP–CD81 by
ELISA, where the data are presented as optical density at 450 nm (C). Flow cytometric binding of anti-CD81 2s20 to parental HepG2 and cells
transduced to express DsRED-CD81 (D). Anti-CD81 mAb binding to HepG2 cells expressing WT DsRED-CD81 and mutant proteins. mAb
binding is expressed as mean fluorescence intensity (MFI) relative to DsRED CD81 signals (E). The data presented are from a single
experiment and are representative of two independent experiments.
Modelling the CD81/claudin-1 receptor for HCV 1897
© 2012 Blackwell Publishing Ltd, Cellular Microbiology, 14, 1892–1903
cells expressing K148A or K148A/T149A CD81 supported
virus infection at comparable levels to WT CD81 (Fig. 4D).
MLVpp infected parental and mutant CD81 expressing
HepG2 cells at comparable levels (Fig. 4D). In summary,
these data confirm the essential role for T149, E152 and
T153 residues of CD81 in virus entry and association with
claudin-1.
Discussion
We applied a bio-informatic modelling-based mutagen-
esis approach to characterize the CD81/claudin-1 extra-
cellular loop interactions essential for HCV infection. Our
in silico model identified interacting residues between
CD81 and claudin-1 and in vitro mutagenesis confirmed
Fig. 4. Effect of CD81 mutations on claudin-1 association and HCV infection. FRET between AcGFP–claudin-1 and DsRED-CD81 and mutant
proteins expressed in 293-T cells (A). The mean plus 2SD of non-specific FRET values observed in parental non-transfected is indicated by
the dashed line and represents the threshold for the assay. Flow cytometric binding of HCV E2 (strain H77) to parental CHO cells and those
transduced to express DsRED-CD81 (B). HCV E2 strain H77 and JFH-1 binding to CHO cells expressing wild-type (WT) DsRED-CD81 and
mutant proteins. HCV E2 binding is expressed as mean fluorescence intensity (MFI) relative to DsRED CD81 signals (C). HepG2 cells were
transduced to express WT DsRED-CD81 and mutant proteins and evaluated for their ability to support HCVpp or MLVpp infection (D). Flow
cytometry of transduced HepG2 cells confirmed comparable levels of CD81 expression. Data are expressed as specific infectivity where the
value of an envelope deficient pseudoparticle is subtracted from both HCVpp and MLVpp relative light unit (RLU) signals. The dashed line
represents the mean plus 2 SD of HCVpp infection of CD81-negative parental HepG2 cells; levels of infection below this threshold are
considered negative. The data presented are from a single experiment and are representative of two independent experiments.
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their role in HCV entry. We predict that the first extracel-
lular loop of claudin-1 is relatively unstructured, with a
high beta turn composition and two motifs, incorporating
amino acids 33–35 and 63–66, that interact with CD81.
Previous reports have shown that mutation of claudin-1
ECL1 residues 32 and 48 ablated CD81 association and
virus entry (Harris et al., 2010), suggesting a direct role
in receptor complex formation. However, in silico model-
ling of these variants showed the formation of an
a-helical region, leading to a marked change in loop ori-
entation, providing an alternative explanation for their
inability to associate with CD81 and failure to support
HCV infection.
To validate our in silico model we studied a panel of
claudin-1 mutants, previously reported to modulate HCV
entry (Cukierman et al., 2009). We demonstrate a signifi-
cant association between claudin-1 viral receptor activity
and interaction with CD81 in silico and in vitro. Three
claudin-1 mutants (L50A, C54A and C64A – group III)
were predicted to interact with alternative CD81 residues
L162, I182, N184 and F186. All three variants displayed
significant association with CD81 in vitro by FRET analy-
sis and yet failed to support HCV entry, demonstrating that
this altered orientation of the two proteins is receptor
inactive. Of note, all of these residues were previously
reported to be involved in binding HCV E2, suggesting
that the second extracellular loop of CD81 needs to inter-
act with both HCV E2 and claudin-1 to confer virus entry
(Drummer et al., 2002; 2005).
In silico modelling of claudin-7 ECL1 demonstrated
minimal contact with CD81 (Fig. 1E), with the loop pro-
jecting outwards in a similar fashion to the group I
claudin-1 mutants. This projection fills the space that
would be occupied by the a-helix containing CD81 resi-
dues T149, E152 and T153. Introduction of M32I/K48E
changes into claudin-7 (Fig. 1F) re-orientates the loop
and allows claudin-7 C64 to interact with CD81 E152 in a
similar way to that seen for WT claudin-1.
Mutagenesis studies have shown the importance of the
highly conserved claudin motif, W30–GLW51–C54–C64
in HCV entry (Cukierman et al., 2009). Our data provide a
structural rationale for these observations. Mutation of
W30, G49 or W51 induced substantial changes in the
local conformation and orientation of the ECL1 motifs
predicted to interface with CD81, such that group I
claudin-1 mutants disrupt the interaction of region 63–66
with CD81 (Table 1). In contrast, mutation of claudin-1
residues L50, C54 or C64 resulted in more modest
changes to ECL1 orientation, leading to an interaction
with alternative CD81 residues.
In forming tight junctions, claudins form homodimers
between identical claudin molecules and heterodimers
with different claudin family members. The intermolecular
interface of claudin-5 has been shown to include both
aromatic (F147, Y148, Y158) and hydrophilic (Q156,
E159) residues in ECL2 (Piontek et al., 2008). Given the
conserved nature of these residues across the claudin
family, our model is consistent with distinct roles for the
extracellular loops in dimerizing with other claudins and
associating with tetraspanins (Kovalenko et al., 2007).
Our model predicts that a claudin-1 protein is capable of
simultaneous association with other claudin proteins and
CD81.
We confirmed that mutation of CD81 residues T149,
E152 and T153 to alanine reduced claudin-1 association
and HCVpp entry. In contrast, mutation of residue
K148A had no effect on CD81 interaction with claudin-1
in vitro and supported HCVpp infection. Importantly, a
panel of conformation-dependent anti-CD81 antibodies
that neutralize HCV infection (Farquhar et al., 2012)
showed comparable binding to all mutants. These data,
together with the observation that HCV E2 protein bound
mutant and parental CD81 with comparable values,
suggest that the mutations have minimal effect on CD81
conformation. However, a CD81 variant bearing the
double mutation K148A/T149A was receptor active, sug-
gesting that K148A suppresses the receptor inactive
T149A mutant. Our model predicts that CD81 K148
interacts with claudin-1 Y33, whereas T149 interacts
with claudin-1 motif 63–66. Importantly, the K148A/
T149A double mutation reinstates the interaction of
CD81 residue E152 with claudin-1 Q63. Although murine
CD81 differs from human CD81 at 17 of the 87 residues
of the ECL2 domain, the region identified here is con-
served, leading us to speculate that the functions
defined by this motif are similar in both organisms (Flint
et al., 2006). These experimental results validate our
structural predictions and highlight claudin-1 region
63–66 interaction with T149 and E152 of CD81 as the
site of primary molecular association. In contrast, the
33–35 region of claudin-1 appears to determine the ori-
entation and packing of the claudin-1 and CD81 extra-
cellular loops.
Importantly, all of the CD81 mutants studied (K148,
T149, E152 and T153) bound HCV E2, consistent with a
report by Drummer and colleagues that residues outside
this region form the HCV E2 binding site (Drummer
et al., 2002). It is interesting to note that these residues,
which were identified by in silico modelling and verified
by site-directed mutagenesis, have previously been
shown to have a role in the association between the
ECL1 and ECL2 domains of CD81, suggesting that this
region may have a role in both homotypic and hetero-
typic interactions of CD81 (Yalaoui et al., 2008). Our
data suggest that distinct regions of CD81 ECL2 engage
HCV glycoproteins and claudin-1, highlighting the poten-
tial to form a ternary HCV/CD81/claudin-1 complex.
Although claudin-1 does not appear to modulate the
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ability of CD81 to bind HCV E2 (data not shown),
claudin-1 limits CD81 lateral movement at the plasma
membrane and promotes receptor endocytosis (Farqu-
har et al., 2012; Harris et al., 2012), suggesting a role for
the CD81–claudin-1 complex in virus internalization and
fusion with early endosomes. Our data uncover a novel
role for CD81 residues T149, E152 and T153 in HCV
entry independent of viral glycoprotein-receptor interac-
tion, and substantiate the key role of CD81–claudin-1
complexes in HCV internalization. Our model of the
CD81/claudin-1 interface provides a new conserved
target for anti-viral drug design and will allow the rational
design of small molecule and peptide mimetics targeting
the receptor complex.
Experimental procedures
Structural modelling
The CD81/claudin-1 complex structure was modelled using
a homology pipeline (http://membraneproteins.swan.ac.uk/
modelling/), assembled in the Biskit structural bioinformatics plat-
form (Grunberg et al., 2007) and scans the entire PDB database
for candidate homologues. The pipeline incorporates the NCBI
tools platform (Wheeler et al., 2008), the BLAST program (Altschul
et al., 1990) for similarity searching of sequences, T-COFFEE
(Notredame et al., 2000) for alignment of candidate sequences
with the template, the MODELLER program (Eswar et al., 2003) for
model assembly and the DSSP algorithm (Kabsch and Sander,
1983) for secondary structure validation. This pipeline has been
employed in the structural modelling of several membrane
protein families (Sanner et al., 1996; Yang et al., 2009; Chung
et al., 2010; Mullins et al., 2010; 2011). Homology models were
generated using 10 iterations of the MODELLER program. Interac-
tions between the structural models of claudin-1 WT or mutants
and known CD81 crystal structure (PDB: 1G8Q) (Kitadokoro
et al., 2001) were simulated using Hex 5.0 (Mustard and Ritchie,
2005), optimally fitting for shape and electrostatic interactions.
Surface areas were calculated using the MSMS package (version
1.3; Sanner et al., 1996).
Cell lines
293-T, HepG2 and CHO cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum, 1% L-Glutamine and 1% non-essential amino
acids (Invitrogen, Carlsbad, CA).
Genesis and fluorophore tagging of CD81 and claudin-1
Claudin-1 mutants were kindly provided by Tatjana Dragic (Albert
Einstein University, NY) and open reading frames (ORFs) ampli-
fied with Phusion™ High-Fidelity DNA Polymerase (New England
Biolabs) with gene-specific primers (Table S1). Amplicons were
cloned into pJET2.1 plasmid (CloneJET system, Fermentas, UK),
sequenced and subcloned into either pBABEpuro or pTRIP
(Zennou et al., 2001; Harris et al., 2010). An AcGFP or DsRED
fluorophore coding region was inserted at the N-terminus of the
protein (Harris et al., 2010). CD81 mutants were generated using
a series of mutagenic primers designed to exploit silent SalI or
SacI sites in the CD81 ORF (Table S1). The 5′ and 3′ halves of
CD81 were amplified, digested and ligated into pJET2.1 to
produce full-length CD81 ORFs encoding the desired mutations
that were transferred into pTRIP-AcGFP or pTRIP-DsRED plas-
mids and sequenced.
Measurement of interaction between CD81 and
claudin-1 by mammalian two-hybrid association
The WT CD81 and mutated claudin-1 molecules were trans-
ferred into pBIND-RLuc(GAL4) and pACT(VP16) vectors respec-
tively (Promega ‘Checkmate’ system). Interaction between the
two proteins was detected in vitro by co-transfecting 293-T cells
with these constructs and a GAL4/VP16 driven pG5FLuc
reporter plasmid, the levels of Renilla luciferase obtained from
the pBIND vector acts as an internal control for transfection
efficiency. Known interacting proteins (pBIND-Id and pACT-
MyoD) and empty vectors were used as positive and negative
controls respectively. After 24 h interaction between the con-
structs was detected by measuring levels of Firefly luciferase
(FLuc), in accordance with the manufacturer’s instructions
(Promega).
Pseudoparticle generation and infection
Pseudoviruses expressing a luciferase reporter were generated
as previously described (Hsu et al., 2003). Briefly, 293-T cells
were transfected with a 1:1 ratio of plasmids encoding HIV pro-
virus expressing luciferase and HCV strain H77 E1E2 envelope
glycoproteins (HCVpp) and Murine Leukaemia virus envelope
glycoprotein (MLVpp) or empty vector (Env-pp). Supernatants
were harvested 48 h post transfection, filtered and virion associ-
ated p24 determined using a commercial assay (Aalta Biorea-
gents). Infection was quantified by measuring luciferase activity
(relative lights units, RLU) and specific infectivity determined by
subtracting the mean Env-pp signal from the HCVpp and MLVpp
values.
CD81 and claudin-1 FRET analysis
FRET analyses were performed as previously described (Harris
et al., 2010). Briefly, 293-T or HepG2 cells were transfected to
express the fluorescent-tagged CD81 and claudin-1 proteins,
grown on 22 mm diameter borosilicate glass coverslips and
imaged using a Zeiss MetaHead LSM confocal system. FRET
was assessed before and after photobleaching at 561 nm to
ablate AcGFP to DsRED energy transfer. Using the microscope’s
built in profiling function, the fluorescence intensities of several
hundred pixels at the plasma membrane were determined at the
light frequencies of the two fluorophores and the stoichiometry of
labelled proteins measured as previously described (Zheng and
Zagotta, 2004; Staruschenko et al., 2005; Harris et al., 2010).
When regression analysis indicated a significant association
between the fluorophores we assessed the occurrence of FRET
between the pixels using a gradual acceptor photobleaching
method (Zal and Gascoigne, 2004). Briefly, the fluorescence
intensity of the AcGFP fluorophore (the donor fluorophore) was
determined before and after photobleaching, with an increase in
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signal indicating the occurrence of FRET. The frequency of pixels
in which FRET was detected gives a measure of AcGFP–DsRED
interaction, recorded as the percentage FRET (Harris et al.,
2008). Statistical analyses were performed using a non-
parametric one-way ANOVA (Kruskal Wallis test) or Student’s
t-test in Prism 4.0, where necessary corrections for multiple com-
parisons were made.
Anti-CD81 mAbs
Anti-CD81 mAbs 1s337, 2s20 and 2s155 were generated follow-
ing immunization of mice with recombinant full-length CD81
(Jamshad et al., 2008). Purified mouse immunoglobulin was a
gift from M. Goodall (University of Birmingham). CD81 MBP-
LEL113-201 (MBP–CD81) was expressed in Escherichia coli
strain BL21 cells as previously reported (Drummer et al., 2002).
Bacteria were lysed by sonication in S-buffer (300 mM NaCI,
100 mM Tris pH 8.0, 1 mM EDTA, 0.02% sodium azide) and
cell debris pelleted by centrifugation at 39 000 g for 30 min.
MBP–CD81 fusion proteins were affinity-purified from the soluble
fraction using amylose-agarose (New England Biolabs) as rec-
ommended by the manufacturer and proteins eluted with 10 mM
maltose. Monomeric and dimeric MBP–CD81 were isolated by
Superdex 200 gel filtration chromatography (Amersham) and
protein purity assessed by SDS/PAGE. mAbs were screened
for their reactivity with native and heat denatured MBP–CD81
and 15-mer peptides overlapping CD81 ECL2. All mAbs failed
to interact with peptides or denatured protein, leading us to
conclude that they recognize conformation-dependent ECL2-
specific epitopes.
CD81–HCV E2 binding
To determine the effect of CD81 mutations on HCV E2 glycopro-
tein binding, WT or mutant CD81 were expressed in CHO cells
using the pTRIP expression system. CHO cells do not bind HCV
E2 and provide a model system to study exogenous human
receptor affinity for HCV E2. Cells were seeded at 2 ¥ 105 cells
per well in a 96 U bottomed well plate in PBS/0.5% BSA/0.01%
sodium azide for 20 min, incubated with HCV strain H77 and
JFH-1 E2661 tagged at the C-terminus with a HIV epitope tag at
5 mg ml-1 diluted in PBS/0.5% BSA/0.01% sodium azide and
incubated for 45 min at 37°C. Unbound HCV E2 was removed by
washing with PBS and bound antigen detected with mAb 10/76b,
which recognizes a HIV gp120 epitope tag (Flint et al., 1999).
After 45 min at 37°C the cells were washed and incubated with
a 1:1000 dilution of an Alexa-633 ant-Rat IgG (Invitrogen,
Carlsbad, CA) for a further 45 min at 37°C. Cells were washed,
fixed with 4% paraformaldehyde and bound HCV E2 visualized
by flow cytometry.
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